Background: EIF5A2, eukaryotic translation initiation factor 5A2, is associated with several human cancers. In this study, we investigated the role of EIF5A2 in the metastatic potential of localised invasive bladder cancer (BC) and its underlying molecular mechanisms were explored.
Bladder cancer (BC) is one of the leading causes of morbidity and mortality in the United States and is the fourth most common cancer in men in the United States, with 54 610 new cases diagnosed in 2013 (Siegel et al, 2013) . Radical cystectomy is necessary in invasive BC and may have a significant impact on the quality of life of patients. However, only 23-46% patients who underwent radical cystectomy can survive for more than 5 years (Pelucchi et al, 2006) , which means that more than half of the invasive BC patients who underwent radical cystectomy died of tumour metastasis. Therefore, the high metastasis of BC after radical cystectomy surgery has always been the major obstacle in the enhancement of survival rate in clinical treatment. According to current studies, BC metastasis was believed to be a multistep process driven by the accumulation of genetic alterations (Nguyen et al, 2009) . The loss of tumour suppressor genes and activation of oncogenes are central events in the development and progression of BC (Pelucchi et al, 2006) . Therefore, it is necessary to investigate the molecular mechanisms of the genes closely related to the metastasis of BC with the goal of improving the intervention of BC.
The eukaryotic initiation factor 5A2 (EIF5A2) gene, located on chromosome 3q26, was first discovered in the primary ovarian cancer cell line in 2001 and has been classified as an oncogene (Guan et al, 2001 ). Then Guan et al (2004) demonstrated an oncogenic role of EIF5A2 in ovarian cancer tumorigenesis. Overexpression of EIF5A2 predicts poor prognosis in gastric adenocarcinomas (Marchet et al, 2007) , colorectal cancer (Xie et al, 2008; Zhu et al, 2012) , hepatocellular carcinomas (Tang et al, 2010) , ovarian cancer (Yang et al, 2009 ) and non-small cell lung cancer (He et al, 2011) . Further studies reveal that EIF5A2 stimulates cell cytoskeleton rearrangement through the activation of Rho/Rac GTPase to induce hepatocellular carcinoma invasiveness (Tang et al, 2010) . In colorectal carcinoma, EIF5A2 upregulates metastasis-associated protein 1(MTA1) through c-myc to induce EMT and promote aggressiveness . Our previous studies demonstrated that EIF5A2 overexpression correlates with shortened survival of BC patients treated with radical cystectomy (Chen et al, 2009) . To date, however, the function of EIF5A2 in localised invasive BC and its underlying molecular mechanisms are still unclear.
Herein, we report that overexpression of EIF5A2 in localised invasive BC is important in the acquisition of a metastatic phenotype. Knockdown of EIF5A2 in BC cells inhibits cell migration and invasion in vitro and metastatic potential in vivo and reversed EMT, whereas overexpression of EIF5A2 promotes BC cell migratory and invasive in vitro and metastatic potential in vivo and induced EMT. Overexpression of EIF5A2 in BC cells elevated the stability of STAT3 and stimulated nuclear localisation of STAT3, which resulted in increasing enrichment of STAT3 onto TGF-b1 promoter to enhance its transcription. TGF-b1 upregulation by EIF5A2 in BC cells was partly dependent on STAT3. Our results provide functional and mechanistic links between EIF5A2 and EMT in the aggressiveness of BC.
MATERIALS AND METHODS
Patients. On institutional review board approval, we identified 154 patients with localised invasive BC treated with radical cystectomy between 2002 and 2007 at First Affiliated Hospital, Jiangmen Hospital of Sun Yat-Sen University and Yuhuangding Hospital of Qingdao University Medical College. None of the patients received adjuvant therapy. Data collected from each patient included gender, age at diagnosis, grade, stage, and metastasis-free survival time. The histologic grade and stage were reassessed according to the 1973 WHO grading system and the 2009 TNM classification system, respectively. Localised invasive BC is defined as histologically verified pathologic tumour stage greater than or equal to 1, no lymphatic metastasis and no distant metastasis disease (Stenzl et al, 2011) . Metastasis-free survival was determined from the date of surgery to the date of the first clinical evidence of metastasis, and was censored at the date of death from other causes or the date of the last follow-up visit for survivors. Paraffin specimens were obtained by radical cystectomy, and 30 cases of normal bladder mucosa from adjacent nonneoplastic bladder tissue of the same BC patients were also obtained. Ten pairs of cancer tissues and adjacent normal bladder specimens were snap-frozen in chilled liquid nitrogen and stored at -80 1C until further processing. The study was approved by the medical ethics committee of each participating institute. No informed consent (written or verbal) was obtained for the use of the retrospective tissue samples from the patients within this study. Informed consent was not deemed necessary by the Ethics Committee, who waived the need for consent. All the samples were anonymous. Cell cultures and stable transfectants. Human bladder transitional cell lines T24 and 5637 were purchased from the American Type Culture Collection (Rockville, MD, USA). The EJ and BIU-87 cells were kindly supplied by the Institute of Urology, Beijing Medical University (Beijing, China). Four BC cell lines-EJ (derived from an advanced grade IV transitional cell carcinoma), BIU-87 (established from the bladder papillary urothelial carcinoma (T1G2)), 5637 (derived from the primary grade II bladder carcinoma), and T24 (established from a highly malignant grade III human urinary bladder carcinoma) -were maintained in RPMI-1640 supplemented with 10% fetal bovine serum. TGF-b1 was purchased from PeproTech (Hamburg, Germany). Untreated controls received vehicle alone. The EIF5A2 complementary DNA (Fulengen, Guangzhou, China) was cloned into pcDNA3.1 plasmid. Cells were transfected with pcDNA-EIF5A2 or the control plasmid pcDNA3.1( þ ) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. For the establishment of the 5637-EIF5A2 cell line stably expressing EIF5A2, 48 h after transfection, the cells were split at a ratio of 1 : 10. Next, cells were maintained in Leibovitz's L-15 medium containing 200 mg ml À 1 of G418 (Calbiochem, San Diego, CA, USA). After 6 weeks of selection, resistant colonies stably transfected with pcDNA-EIF5A2 (EIF5A2 expression vector) or pcDNA3.1( þ ) (empty vector) were pooled.
RNA interference. Short interfering RNA specifically against EIF5A2 (Tang et al, 2010) , TGF-b1 and STAT3 transfected into BC cells in 6-well plates using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. The oligoribonucleotide sequence of short interference RNA to repress TGF-b1 and STAT3 are listed as follows: TGF-b1 sense: 5 0 -UGGU GAAGCGGAAGCGCAUUU-3 0 ; TGF-b1 antisense: 5 0 -AUGCGC UUCCGCUUCACCAUU-3 0 . STAT3 sense: 5 0 -GGAGAAGCAUC GUGAGUGAUU-3 0 STAT3 antisense: 5 0 -UCACUCACGAUGCU UCUCCUU-3 0 . The sequence of human short hairpin RNA (shRNA) sequences to repress EIF5A2 expression (shEIF5A2) is 5 0 -GCTAGCAGCTTATCAGGAAGGAA-3 0 . Vector construction, lentivirus production and infection were performed as described previously . Human BC EJ cells were infection with shEIF5A2 (EJ-shEIF5A2) and control scramble shRNA (EJ-scramble), respectively. The gene silencing effect was measured by western blotting 48 h post transfection.
RNA extraction, reverse transcription and quantitative PCR. See Supplementary Materials and Methods (available online only) for details.
Wounding healing and invasion assays. Cell migration was assessed by measuring the movement of cells into a wound -a scraped, a cellular area made by a 200 ml pipette tube. Wound closure was observed after 48 h. Invasion assays were performed with 24-well BioCoat Matrigel Invasion Chambers (BD Biosciences, San Diego, CA, USA) according to the manufacturer's instructions. Briefly, 2 Â 10 4 cells were seeded into 8 mm pore inserts in triplicate wells and incubated for 24 h. The invaded cells in lower filters were fixed in methanal and stained in crystal violet (Sigma, St Louis, MO, USA) followed by counting under microscope. All experiments were repeated three times and a representative result was presented.
Immunofluorescence analysis. Cells were incubated with primary antibodies against E-cadherin, a-catenin, vimentin, fibronectin (Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1 : 100 dilution), EIF5A2 (Abnova, Jhongli, Taiwan, 1 : 100 dilution) or STAT3 (BD Biosciences, 1 : 100 dilution) overnight at 4 1C and then incubated with rhodamine-conjugated or FITC-conjugated goat antibodies against rabbit or mouse IgG (Jackson Immuno-Research Laboratories, Westgrove, PA, USA). The coverslips were counterstained with DAPI (Vector Laboratories, Burlingame, CA, USA) and imaged with a confocal laser scanning microscope Olympus FV1000 (Tokyo, Japan).
Tumour metastasis in nude mice. Female BALB/c-nu/nu athymic mice (4-5 weeks old), purchased from Shanghai Slac Laboratory Animal (Shanghai, China), were kept under specific pathogen-free conditions and cared for in accordance with the guidelines of the laboratory animal ethics committee of Sun Yat-Sen University. Eight mice in each experimental group were injected with EJ-scramble, EJ-shEIF5A2, 5637-EIF5A2 and 5637-vector cells separately. Briefly, 2 Â 10 5 cells were injected intravenously through the tail vein into each mouse in a laminar flow cabinet. Six weeks after cell injection, mice were killed and examined. All the procedures are in accordance with the guidelines of the laboratory animal ethics committee of Sun Yat-Sen University.
Chromatin immunoprecipitation (ChIP) assays. See Supplementary Materials and Methods (available online only) for details.
Dual luciferase reporter assay. Dual luciferase reporter assay was performed as described previously with slight modification. Briefly, PCR was performed to amplify human TGFb1 promoter sequences ( À 3363 to þ 110). The PCR product was subcloned into the pGL3 luciferase reporter construct (Promega, Madison, WI, USA). The treated 5637 cells were lysed, and the activities of the firefly and Renilla luciferases were analysed using a dual luciferase assay kit (Promega) according to the manufacturer's instructions. All reporter gene assays were performed in triplicate and repeated twice. The results were expressed as the mean±s.e.
Statistical analysis. Groups were compared using l 2 test for categorical variables. Survival curves were estimated using the Kaplan-Meier method. The univariate Cox proportional regression hazard model was used to analyse the correlation between variables and clinical outcomes. Multivariate survival analysis was performed on all parameters that were significant on univariate analysis using the Cox regression model. The predictive accuracy of prognostic factors was determined using time-dependent receiver operating characteristic (ROC) analysis for censored data, and the area under the curve (AUC) at 5 year was used to measure predictive accuracy. P-valueso0.05 were considered significant. R software version 2.7.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for time-dependent ROC curve analysis. SPSS software (SPSS Standard version 16.0; SPSS, Chicago, IL, USA) was used for all other calculations.
RESULTS
The expression of EIF5A2 in localised invasive BC. To investigate the expression status of EIF5A2 in BC, we conducted western blotting in 10 fresh BC tissues (T) with their adjacent normal bladder tissues (N). As shown in Figure 1A , EIF5A2 protein levels were elevated in BC tissues compared with adjacent normal bladder tissues. Consistent with these results, immunohistochemical (IHC) analysis revealed a similar trend in BC and the corresponding adjacent noncancerous tissues. Immunohistochemical staining of EIF5A2 in representative samples of BC and normal bladder mucosal tissues is shown in Figure 1B -D. The clinicopathological characteristics of the 154 patients studied were summarised in Table 1. Using the criteria described above, we found overexpression of EIF5A2 in 63 (40.9%) BC. No significant correlation was found between EIF5A2 expression and patient age or gender, or tumour grade, stage, or multiplicity (P40.05, Table 1 ).
Relationship between EIF5A2 expression and localised invasive BC patient clinicopathologic features and survival. A total of 37.0% (57/154) of patients showed tumour metastasis after an average of 31.6 months. Univariate Cox regression analysis identified EIF5A2 expression, pathological stage, and tumour grade to have a significant impact on metastasis-free survival (P ¼ 0.006, 0.006, and 0.009, respectively; Table 2 ). Other clinicopathological variables, including age, gender, and tumour multiplicity, showed no significant correlation with metastasis-free survival (P40.05, Table 2 ). The parameters that were significant in univariate analysis were further examined in Cox regression multivariate analysis. The results showed that the expression of EIF5A2 (P ¼ 0.006, Figure 1E ), tumour stage (P ¼ 0.007), and tumour grade (P ¼ 0.008) were independent predictors of tumour metastasis (Table 2 ).
In addition, we constructed a prognostic model combining three independent prognostic factors (EIF5A2, stage and grade) by Cox proportional hazards regression. Time-dependent ROC curve was used to compare the prognostic validity of the combined model with each factor alone model. As showed in Figure 1F , the model combining EIF5A2, grade, and stage (AUC at 5 year: 0.803; 95% CI: 0.671-0.940) had a better prognostic value than EIF5A2 alone model (AUC at 5 year: 0.640; 95% CI: 0.543-0.736; P ¼ 0.012), tumour grade alone model (AUC at 5 year: 0.640; 95% CI: 0.520-0.754; P ¼ 0.016), and stage alone model (AUC at 5 year: 0.656; 95% CI: 0.526-0.802; P ¼ 0.002). Therefore, the expression of EIF5A2 might add prognostic value to the staging and grading system of BC.
Knockdown of EIF5A2 inhibited BC cell migration and invasion in vitro and metastatic potential in vivo. As the overexpression of EIF5A2 examined by immunohistochemistry was positively associated with BC metastasis, to investigate the impact of EIF5A2 on BC cell invasiveness, we analysed EIF5A2 expression in four tumour-derived BC cell lines by western blotting. T24 and EJ cell lines showed relative higher endogenous EIF5A2 expression compared with 5637 and BIU-87 cell lines both at mRNA and protein levels (Figure 2A ). Both siRNA could efficiently knockdown endogenous EIF5A2 in BC cells ( Figure 2B ). The results showed that knockdown of EIF5A2 caused an apparent suppression of cell migration in both T24 and EJ cell lines using a wound-healing assay ( Figure 2C) . Matrigel invasion assays also demonstrated that ablation of endogenous EIF5A2 markedly reduced the invasive capacity of both T24 and EJ cell lines ( Figure 2D ). To investigate the in vivo effect of EIF5A2 knockdown on metastasis, we used an experimental metastasis assay in which we injected EJ-scramble and EJ-shEIF5A2 into the lateral tail vein of athymic nude mice (eight mice per group). As showed in Figure 2E , the mice injected with EJ-shEIF5A2 cells formed fewer nodes per lung than the mice injected with control shRNA cells (2.875 ± 2.850 versus 13.5 ± 5.632, Po0.001, Mann-Whitney test). Histological studies confirmed that the lesions were caused by extravasation and subsequent tumour growth of EJ cells into the lungs ( Figure 2F ).
Overexpression of EIF5A2 promoted migration and invasion of BC cells in vitro and metastatic potential in vivo. To determine whether overexpression of EIF5A2 could enhance the invasive capacity of BC cells, we constructed a 5637-EIF5A2 cell line, which overexpressed EIF5A2 as demonstrated by western blotting and qPCR ( Figure 3A) . Wound-healing assay demonstrated that overexpression of EIF5A2 enhanced 5637 cell migration at the edge of exposed regions ( Figure 3B ). The matrigel invasion assay showed that 5637-EIF5A2 cells had significantly increased invasive capacity, compared with our control 5637-vector cells ( Figure 3C) .
Simultaneously, the mice injected with 5637-vector cells formed fewer nodes per lung than the mice injected with 5637-EIF5A2 cells ( Figure 3D and E). Our data indicated that EIF5A2 promoted BC cells aggressiveness in vitro and in vivo. a-catenin were elevated while the levels of vimentin and fibronectin decreased by western blotting ( Figure 4A ). On the contrary, after overexpression of EIF5A2 in 5637 cells, the levels of E-cadherin and a-catenin downregulated, whereas the levels of vimentin and fibronectin upregulated, as evidenced by both western blotting ( Figure 4B ) and immunofluorescence staining assays ( Figure 4C ). In addition, IHC staining of EMT markers (E-cadherin, a-catenin, vimentin and fibronectin) in our cohort of BC tissue microarray (TMA) tissues was utilised to analyse the EIF5A2 and EMT markers expression patterns in BC. Consistently, our IHC analysis in BC TMA samples further confirmed that EIF5A2 expression level positively correlated to the expression levels of vimentin and fibronectin, and inversely correlated to the expression levels of E-cadherin and a-catenin (Supplementary Table S1 , available online only). Figure 4D shows the representative immunohistochemistry results.
EIF5A2 upregulated TGF-b1 to induce EMT and promote aggressiveness in BC cells. To obtain further insight into the molecular mechanisms of EIF5A2 in BC cell aggressiveness, messenger RNA expression profiles of EJ-shEIF5A2 cells were compared with those of control EJ-scramble cells using a human tumour metastasis RT 2 profiler PCR array containing 84 cell metastasis-related genes. The results indicated that E-cadherin (i.e. cadherin 1), CTNNA1, TGF-b1, TIMP2, TIMP3 and TIMP4 genes showed more than a two times change in mRNA levels. (Figure 5A and Supplementary Table S2, available online only). Subsequently, these downstream targets were selected and further validated by a western blotting assay. Consistent with those of mRNA expression in real-time PCR array, decreased TGF-b1 and increased E-cadherin and CTNNA1 in protein levels were examined by western blotting in EIF5A2 knockdown EJ cells ( Figure 5B ). To investigate whether TGF-b1 is required for EIF5A2-induced BC cell EMT and invasiveness, we conducted RNA interference to knockdown TGF-b1 expression in 5637-EIF5A2 cells. After siTGF-b1 treatment, EIF5A2-induced EMT was significantly inhibited ( Figure 5C and F) . In addition, woundhealing and matrigel invasion assays showed that the migratory and invasive capacities of 5637-EIF5A2 cells were all dramatically inhibited after the silencing of TGF-b1 ( Figure 5D and E). In contrast, TGF-b1 introduction into EIF5A2-silenced T24 and EJ cells could restore their aggressive phenotype (see Supplementary Figure S1 , available online only). These data, taken together, provided evidence that TGF-b1 was responsible for the EIF5A2-induced EMT and invasiveness in BC cells.
EIF5A2 stabilized STAT3 and stimulated nucleus localisation of STAT3 to augment enrichment of STAT3 onto TGF-b1 promoter. TGF-b1 has been shown to be regulated by transcription factors such as NF-kB (Lin et al, 2010) , Sp1 (Kim et al, 1998) , androgen receptor (AR) (Qi et al, 2008) , upstream stimulatory factor 1 (USF1) (Weigert et al, 2004) and signal transducer and activator of transcription 3 (STAT3) (Ogata et al, 2006) . We wondered whether EIF5A2-mediated TGF-b1 upregulation is associated with these transcription factors in BC cells. As anticipated, the ChIP results demonstrated that in the 5637-EIF5A2 cells, the enrichment of STAT3 was substantially enhanced, however, we did not find alternative recruitment of NF-kB, Sp1, AR and USF1 compared with that in control 5637-vector cells (Figure 6A ). At the same time, western blotting revealed that, compared with vector cells, expression of STAT3 significantly increased in 5637-EIF5A2 cells. However, real-time PCR shows no significant change in STAT3 mRNA ( Figure 6B ), suggesting that modulation of STAT3 expression might be due to posttranslational modification. To assess the effect of EIF5A2 on STAT3 stability, protein half-life of STAT3 was estimated by treating with 20 mM cycloheximide for the indicated times. As showed in Figure 6C , the half-life of STAT3 was determined to be B16 h in 5637-vector cells, which is consistent with a previous report (Jain et al, 2012) . However, its half-life dramatically increased to more than 24 h in 5637-EIF5A2 cells. On the other hand, knockdown of EIF5A2 expression reduced the half-life of STAT3 protein in T24 cells. At the same time, immunofluorescence staining revealed EIF5A2 also affected the STAT3 subcellular localisation. As shown in Figure 6D , STAT3 localised to both the nucleus and cytoplasm in 5637-vector cells, whereas it was mainly detected in the nucleus of 5637-EIF5A2 cells. The translocation of STAT3 between 5637-vector cells and 5637-EIF5A2 cells was confirmed by western blotting analyses of cytoplasmatic and nuclear extracts ( Figure 6E) . Furthermore, the dual luciferase reporter assay showed that knocking down of STAT3 by specific siRNA partly inhibited the transcriptional activity of EIF5A2 on the TGF-b1 promoter (upregulated ratio 4.83 vs 2.05, Figure 6F ). Further studies demonstrated that EIF5A2-mediated the upregulation of TGF-b1 expression, EMT and the migratory/invasive capacity of 5637-EIF5A2 cells were partly prevented, when STAT3 was knocked down (Figure 5 ).
DISCUSSION
In this study, the protein expression of EIF5A2 was examined in BC tissues of 154 localised invasive BC patients treated with radical cystectomy. We demonstrated that overexpression of EIF5A2 in localised invasive BC was an independent predictor for poor metastasis-free survival. More important, our molecular mechanisms study showed that EIF5A2 promoted BC aggressiveness by upregulating TGF-b1 through STAT3 to induce EMT.
The EIF5A2 gene, located on chromosome 3q26, has been identified as an oncogene (Guan et al, 2001 (Guan et al, , 2004 . Since then, EIF5A2 has been found to be overexpression in diverse human malignancies and is associated with tumour progression, lymph node metastasis and poor prognosis (Marchet et al, 2007; Xie et al, 2008; Yang et al, 2009; Tang et al, 2010; He et al, 2011; Zhu et al, 2012) . In this study, univariate and multivariate Cox regression analysis also indicated that EIF5A2 was an independent prognostic factor to metastasis-free survival of patients with localised invasive BC, which was consistent with our previous finding (Chen et al, 2009) . To clarify the biological function of EIF5A2 in BC cells, a series of in vitro and in vivo experiments were conducted. The results showed that siRNA mediated EIF5A2 knockdown in T24 and EJ cells, inhibited BC cell to migrate or invade and reduced EMT. On the contrary, it was opposite results in EIF5A2 overexpression 5637 cells. In a tail vein injection mouse model of cancer metastasis, knockdown of EIF5A2 decreased the cancer cells metastatic potential in vivo, while overexpression of EIF5A2 led to a significant increase in the number of lesions of lung metastasis. These data indicated that EIF5A2 induced EMT and promoted aggressiveness in BC cells. To investigate the underlying molecular mechanisms involving EIF5A2 and BC EMT and aggressiveness, we compared mRNA expression profiles between EJ-shEIF5A2 cells and EJ-scramble cells using a human tumour metastasis real-time PCR array, containing 84 well-known cell invasion/metastasis-related genes. We found that E-cadherin (i.e. cadherin 1), CTNNA1, TGF-b1, TIMP2, TIMP3 and TIMP4 genes showed more than a two times change in mRNA levels. Subsequently, upregulation of E-cadherin and a-catenin, downregulation of TGF-b1 were validated in protein levels by western blotting in EJ-shEIF5A2 cells. In this study, the mRNA expression level of MTA1 in 5637-EIF5A2 cells only slightly elevated by real-time PCR array. However, our previous finding showed that EIF5A2 is responsible for the activation of MTA1 in colorectal carcinoma . We conducted western blotting to further confirm the protein expression levels of MTA1 in BC cells. Our western blotting results showed no significant upregulation of MTA1 in 5637-EIF5A2 cells compared with 5637-vector cells (data not shown). The discordance might be explained as the molecular mechanisms by which EIF5A2 regulates cancer cell aggressiveness might be tumour-type special.
TGF-b1 promotes tumour progression in advanced stages by inducing tumour invasion, EMT, and metastasis (Massague, 2008) . TGF-b1 has been demonstrated to have an important role in many cancers cell invasiveness, EMT, and metastasis (Han et al, 2005; Natsuizaka et al, 2010; Zhang et al, 2011; Wendt et al, 2013) . Previous studies also reported that TGF-b1 is upregulated in BC tissue relative to benign tissue (Eder et al, 1997) , and TGF-b1 levels are elevated in the plasma and peritoneal fluid of BC patients (Eder et al, 1996; Shariat et al, 2001; Eissa et al, 2007) . To determine if TGF-b1 is a downstream target involved in EIF5A2-induced BC cell EMT and aggressiveness, we silenced TGF-b1 by siRNA in 5637-EIF5A2 cells. We found that the enhancement of EIF5A2 on migratory/invasive capacities and EMT dramatically vanished when TGF-b1 was knocked down. On the other hand, when TGF-b1 was introduced in EIF5A2-silenced T24 and EJ cells, the migratory/invasive and EMT phenotypes of BC cells were substantially rescued. These data suggested that TGF-b1 might be a critical downstream target of EIF5A2 and was responsible for the EIF5A2-induced EMT and invasiveness in BC cells. To date, however, the mechanisms by which EIF5A2 regulates TGF-b1 expression have not been elucidated. TGF-b1 has been shown to be regulated by transcription factors such as NF-kB, Sp1, AR, USF1, and STAT3 in various experimental systems (Kim et al, 1998; Weigert et al, 2004; Ogata et al, 2006; Qi et al, 2008; Lin et al, 2010) . In the present study, we did not find the incremental enrichment of NF-kB, Sp1, AR, and USF1 on the promoter of TGF-b1; however, the enrichment of STAT3 on the TGF-b1 promoter was substantially enhanced after the overexpression of EIF5A2. Subsequently, we observed the upregulation level of STAT3 in 5637-EIF5A2 cells, whereas real-time PCR shows no significant change in STAT3 mRNA. We speculated that the discordance between STAT3 mRNA and protein levels might be explained by EIF5A2 mediated posttranslational modification of STAT3. As our anticipated, our results showed that EIF5A2 stabilized STAT3 and stimulated STAT3 translocation to the nucleus. High protein levels of STAT3 in the nucleus might responsible for the increment binding of STAT3 to the TGF-b1 promoter to enhance its transcription. In addition, our luciferase reporter assays showed that silencing of STAT3 by siRNA in 5637-EIF5A2 cells only partly inhibited the transcriptional activity of EIF5A2 on the TGF-b1 promoter, and EIF5A2-mediated TGF-b1 upregulation was partly inhibited by knockdown of STAT3. These data imply that besides STAT3, other unknown mechanisms might be involved in the regulation of TGF-b1 by EIF5A2 in BC cells. Clearly, further work is needed to clarify the mechanisms of EIF5A2 regulating TGF-b1 in detail.
In summary, we showed that overexpression of EIF5A2 in localised invasive BC was an independent predictor for poor metastasis-free survival. Further molecular mechanisms study revealed that EIF5A2 elevated TGF-b1 expression through STAT3 to induce EMT and promote aggressiveness in BC. These findings might potentially help us target a subset of the localised invasive BC patient population for more aggressive postsurgical adjuvant anticancer therapies. The molecular mechanisms findings might be responsible, at least partly, for the metastatic potential of localised invasive BC.
